ValuEngine Downgrades Vascular Biogenics (VBLT) to Sell

ValuEngine cut shares of Vascular Biogenics (NASDAQ:VBLT) from a hold rating to a sell rating in a research report released on Wednesday, May 1st, ValuEngine reports.

Other equities research analysts have also recently issued reports about the company. Chardan Capital reiterated a neutral rating on shares of Vascular Biogenics in a research report on Wednesday, March 13th. Zacks Investment Research upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research report on Saturday, March 30th. Finally, HC Wainwright restated a buy rating and issued a $3.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, January 15th.

Shares of VBLT opened at $1.25 on Wednesday. Vascular Biogenics has a twelve month low of $0.60 and a twelve month high of $3.10. The stock has a market cap of $46.29 million, a PE ratio of -2.02 and a beta of -0.25. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.01.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.06). Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 30.67%. The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $2.30 million. As a group, sell-side analysts predict that Vascular Biogenics will post -0.61 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of VBLT. Morgan Stanley lifted its holdings in shares of Vascular Biogenics by 19.7% in the 1st quarter. Morgan Stanley now owns 277,112 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 45,552 shares during the period. Acadian Asset Management LLC raised its position in shares of Vascular Biogenics by 272.3% in the 1st quarter. Acadian Asset Management LLC now owns 59,427 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 43,466 shares in the last quarter. Athena Capital Advisors LLC bought a new position in shares of Vascular Biogenics in the 1st quarter worth $25,000. Menta Capital LLC bought a new position in shares of Vascular Biogenics in the 1st quarter worth $35,000. Finally, First Republic Investment Management Inc. raised its position in shares of Vascular Biogenics by 7.4% in the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 14.06% of the company’s stock.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Article: How do buyers and sellers choose a strike price?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.